BioVie (NASDAQ: BIVI) awards 132,000 options to Chief Medical Officer

Rhea-AI Filing Summary

BioVie Inc. reported that Chief Medical Officer Joseph M. Palumbo received a grant of 132,000 stock options on January 5, 2026.

The options, held directly, have an exercise price of $1.31 per share, were granted at no cost, and are exercisable for 132,000 shares of common stock. According to the vesting schedule, 55% of the options vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. Any unexercised options expire on January 5, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palumbo Joseph M

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		132,000		(1)	01/05/2036	Common Stock	132,000	$0.00	132,000	D

Explanation of Responses:

1. 55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029

	/s/ Joanne Wendy Kim, attorney-in-fact for Joseph M Palumbo, MD	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioVie (BIVI) disclose in this Form 4?

BioVie reported that Chief Medical Officer Joseph M. Palumbo received a grant of 132,000 stock options on January 5, 2026.

What is the exercise price of the BioVie (BIVI) stock options granted to the CMO?

The stock options granted to the Chief Medical Officer have an exercise price of $1.31 per share.

How many BioVie (BIVI) shares underlie the options granted on January 5, 2026?

The stock options are exercisable for 132,000 shares of BioVie common stock.

What is the vesting schedule for the BioVie (BIVI) options granted to the Chief Medical Officer?

55% of the options vested on January 5, 2026, and the remaining options vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

When do the BioVie (BIVI) stock options granted to the CMO expire?

The options expire on January 5, 2036 if they are not exercised before that date.

Were the BioVie (BIVI) options granted to the Chief Medical Officer held directly or indirectly?

The Form 4 shows the 132,000 stock options as being held directly by the reporting person.

Did the Chief Medical Officer pay anything for the BioVie (BIVI) option grant?

The Form 4 indicates the options were granted at a price of $0.00 for the derivative security, meaning there was no cost to receive the grant.